The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of the androgen signaling inhibitor ARN-509 in patients with castration-resistant prostate cancer (CRPC).
Dana E. Rathkopf
Research Funding - Aragon Pharmaceuticals
Neal Shore
No relevant relationships to disclose
Emmanuel S. Antonarakis
Consultant or Advisory Role - Sanofi
William R. Berry
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Ronald Tutrone
No relevant relationships to disclose
Mansoor N. Saleh
No relevant relationships to disclose
Charles H. Redfern
No relevant relationships to disclose
Ralph J. Hauke
No relevant relationships to disclose
Glenn Liu
No relevant relationships to disclose
Jill Elise Steinbrecher
No relevant relationships to disclose
Daniel Costin Danila
No relevant relationships to disclose
Tracy Curley
No relevant relationships to disclose
Gabrielle Arauz
No relevant relationships to disclose
Peter J. Rix
Employment or Leadership Position - Aragon Pharmaceuticals
Stock Ownership - Aragon Pharmaceuticals
Edna Chow Maneval
Employment or Leadership Position - Aragon Pharmaceuticals
Stock Ownership - Aragon Pharmaceuticals
Isan Chen
Employment or Leadership Position - Aragon Pharmaceuticals
Stock Ownership - Aragon Pharmaceuticals
Howard I. Scher
Consultant or Advisory Role - Aragon Pharmaceuticals (U)
Research Funding - MSKCC